Bristol Myers Squibb Company $BMY Shares Acquired by Amundi

Amundi grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 12.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,474,537 shares of the biopharmaceutical company's stock after purchasing an additional 800,539 shares during the period. Amundi owned approximately 0.37% of Bristol Myers Squibb worth $430,681,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. California State Teachers Retirement System boosted its stake in Bristol Myers Squibb by 5,484.7% in the 2nd quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company's stock worth $10,674,449,000 after purchasing an additional 181,938,762 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. State Street Corp lifted its stake in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company's stock worth $5,285,065,000 after buying an additional 1,385,206 shares during the period. Geode Capital Management LLC lifted its stake in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after buying an additional 6,084,046 shares during the period. Finally, Norges Bank purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at $1,947,272,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

BMY has been the topic of several research reports. Citigroup reissued a "neutral" rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. JPMorgan Chase & Co. increased their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Jefferies Financial Group cut Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research note on Wednesday, August 5th. Finally, Guggenheim reaffirmed a "buy" rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Trading Up 0.0%

Shares of BMY stock opened at $66.85 on Tuesday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The company has a market cap of $136.56 billion, a price-to-earnings ratio of 14.72, a PEG ratio of 0.32 and a beta of 0.23. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock has a 50 day simple moving average of $63.09 and a 200-day simple moving average of $59.96.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.